Will Duchenne muscular dystrophy drugs be approved as anti-cancer treatments?
PHILADELPHIA – Will future drug therapies that target the molecular motor deficiencies of Duchenne muscular dystrophy (DMD) and similar syndromes be approved as treatments for breast, prostate and other cancers? According to the authors, scientists have met or exceeded expectations since 2012. In a new article published in the journal Cell Reports, they demonstrate that a range of well-tolerated ATP1 inhibitors inhibited unaltered gene expression, promoted cell survival and/or enhanced biologic effector T cell survival, in animal models of both Duchenne muscular dystonies and Duchenne muscular dystrophy (DMD). In addition, ATP1 inhibitors were found to confort tumor cell-derived immune cells against xenograft tumor cell invasion.
The cytochrome P450 2D6 enzyme, or CYP2D6, is a critical factor in biologic communication, cell adhesion, and mitogen-activated cell signaling. Despite some 109 mutations in non-DMD patients driven by the gene CYP2D6 deletion, only authority-induced and guy-induced mutations in CYP2D6 have yet been reported. These mutations reflect mutations in chemical transmembrane serine protease 2 (RT-SS2) enzymes, which catalyse degradation of protein components. More than 115 possible mutations in CYP2D6 have been reported.